MedTrace Logo

Treat-to-target With Secukinumab in Axial Spondyloarthritis

NCT03639740 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2019-01-03

No results posted yet for this study

Summary

A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.

Conditions

Interventions

DRUG

Secukinumab 150 milligram [Cosentyx]

For intervention description: see arm/group description

Sponsors & Collaborators

  • Novartis Healthcare A/S

    collaborator INDUSTRY

  • Professor Mikkel Østergaard

    lead OTHER

Principal Investigators

  • Mikkel Østergaard, DMSc PhD MD · Rigshospitalet, Denmark

  • Susanne J Pedersen, MD PhD · Rigshospitalet, Denmark

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639740 on ClinicalTrials.gov